Results 41 to 50 of about 2,820 (114)

Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies

Biopharmaceutics &Drug Disposition, EarlyView.
This study identified new optimal allometric scaling exponents for human PK prediction of monoclonal antibodies with linear PKs from marmoset PK data. In addition, immunogenicity in common marmosets was evaluated following the repeated dose of golimumab and ustekinumab, minimal anti‐drug antibodies were detected.
Ayaka Tajiri, Shogo Matsumoto, Nanami Furukawa, Kensuke Kagiyama, Hiroshi Ikeda, Kazumasa Fukasawa, Hiroki Takano   +6 more
wiley   +1 more source

Long‐term outcomes of children with ulcerative colitis after acute severe colitis: A GETAID pédiatrique multicenter study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Acute severe colitis (ASC) is a frequent and severe complication of ulcerative colitis (UC) with a high risk of colectomy. Effects of immunosuppressants and anti–tumor necrosis factor (anti‐TNF) agents on the risk of colectomy remain debated. We wished to study the evolution of French pediatric‐onset UC patients after ASC.
Manon Cochet, Agathe Beauvais, Frank Ruemmele, Raphael Enaud, Thierry Lamireau, Rémi Duclaux‐Loras, Claire Dupont, Stéphanie Willot, Laure Bridoux‐Henno, Georges Dimitrov, Julie Lemale, Vincent Guinard‐Samuel, Valérie Bertrand, Anne Breton, Christine Martinez Vinson, Stéphanie Coopman, Delphine Ley, Bénédicte Pigneur, and the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du tube Digestif (GETAID) pédiatrique   +18 more
wiley   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source

Five‐Year Outcomes and Disease Trajectories in Moderate‐to‐Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim The incidence of ulcerative colitis (UC) has been increasing in Asia. Comprehensive data on the long‐term course of moderate‐to‐severe UC remain scarce. This study investigated the clinical outcomes and factors associated with a disabling disease course in Korean patients with moderate‐to‐severe UC.
Byong Duk Ye, Hyo Jong Kim, Dong Il Park, Young Sook Park, Kang‐Moon Lee, Jong Pil Im, Sung‐Ae Jung, Yoon Tae Jeen, Jae Myung Cha, Jae Hee Cheon, Sung Noh Hong, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Chang Kyun Lee   +14 more
wiley   +1 more source

The role of neutrophils in the pathophysiology of inflammatory bowel diseases

Periodontology 2000, EarlyView.
Abstract Objectives Inflammatory bowel disease (IBD) encompasses a spectrum of chronic disorders of the gastrointestinal tract, with a potential bidirectional relationship with periodontitis. Neutrophils are key regulators of immune‐inflammatory responses and play a major role in both diseases.
Joao Paulo Steffens, Ekin Yay‐Kus, Rafael Scaf de Molon, Viorelia Stoica, Peter Rimmer, Josefine Hirschfeld, Asif Jilani Iqbal, Tariq Iqbal, Iain Chapple   +8 more
wiley   +1 more source

2024 Update of the Asia‐Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management

International Journal of Rheumatic Diseases, Volume 29, Issue 7, July 2026.
ABSTRACT Aim To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier ...
Kunihiro Yamaoka, Zhanguo Li, Khin Thin Zar Myo Aung, Paul Bird, Manisha Bhochhibhoya, Minhaj Rahim Choudhury, Debashish Danda, Tsolmon Darisuren, Rudy Hidayat, Nguyen Van Hung, Yuko Kaneko, Wanruchada Katchamart, Manjari Lahiri, Chin Teck Ng, Babur Salim, Keshav Raj Sigdel, Shereen Ch'ng Suyin, Tsutomu Takeuchi, Galymzhan Togizbayev, Evan Vista, Sandini Wijeweera, Chuanhui Xu, Chak Sing Lau   +22 more
wiley   +1 more source

Unravelling a Case of Coronary Vasculitis

Journal of Clinical Rheumatology and Immunology
Background Coronary vasculitis is a rare cause of myocardial infarction through varied mechanisms. We report the case of a 32-year-old female found to have diffuse coronary microaneurysms during treatment for an Inferior ST Elevation Myocardial ...
Raahya Lafir, Inoshi Atukorala, Manudi Vidanapathirana   +2 more
doaj   +1 more source

Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial [PDF]

The Journal of Rheumatology, 2019
Objective.Evaluate effects of intravenous (IV) golimumab (GOL) on radiographic progression in psoriatic arthritis (PsA).Methods.This phase III, randomized, double-blind, placebo-controlled trial (GO-VIBRANT) randomized patients with active PsA to receive IV placebo (n = 239) or IV GOL 2 mg/kg (n = 241) at weeks 0, 4, 12, and 20.
Arthur, Kavanaugh, M Elaine, Husni, Diane D, Harrison, Lilianne, Kim, Kim Hung, Lo, Lenore, Noonan, Elizabeth C, Hsia   +6 more
openaire   +2 more sources

FRI0543 EFFICACY AND SAFETY OF INTRAVENOUS GOLIMUMAB IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM A PHASE 3 OPEN-LABEL STUDY [PDF]

Annals of the Rheumatic Diseases, 2019
Objectives To assess efficacy & safety of intravenous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy through 28 weeks of treatment. Methods A multicenter, Phase 3, single arm, open-label trial was conducted using intravenous golimumab at a dose of 80mg/m2 given at weeks 0 &
Nicolino Ruperto, Alberto Spindler, Cesar Francisco Pacheco Tena, Ingrid Louw, Gabriel Vega Cornejo, Daniel Kingsbury, Michael Clark, Karen Bensley, LI Xiaoming, Hermine Brunner   +9 more
openaire   +1 more source